Voya Investment Management LLC Increases Stock Holdings in Guardant Health, Inc. (NASDAQ:GH)

Guardant Health logoVoya Investment Management LLC increased its position in Guardant Health, Inc. (NASDAQ:GH – Get Rating) by 4.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,371,250 shares of the company’s stock after acquiring an additional 57,207 shares during the quarter. Voya Investment Management LLC owned about 1.34% of Guardant Health worth $37,298,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of GH. Captrust Financial Advisors increased its stake in Guardant Health by 33.2% in the 2nd quarter. Captrust Financial Advisors now owns 1,087 shares of the company’s stock worth $44,000 after acquiring an additional 271 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in Guardant Health in the fourth quarter valued at approximately $48,000. Itau Unibanco Holding SA lifted its position in Guardant Health by 68.7% during the fourth quarter. Itau Unibanco Holding SA now owns 1,760 shares of the company’s stock valued at $48,000 after purchasing an additional 717 shares during the last quarter. Belpointe Asset Management LLC purchased a new position in Guardant Health in the 4th quarter worth approximately $62,000. Finally, PNC Financial Services Group Inc. grew its stake in Guardant Health by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,121 shares of the company’s stock worth $85,000 after buying an additional 729 shares in the last quarter. Hedge funds and other institutional investors own 90.43% of the company’s stock.

Insider Buying and Selling

In other news, Director Meghan V. Joyce sold 2,766 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $37.55, for a total value of $103,863.30. Following the completion of the transaction, the director now owns 4,224 shares in the company, valued at approximately $158,611.20. The transaction was disclosed in a document filed with the SEC, which is available on the SEC website. In other Guardant Health news, insider Kumud Kalia bought 2,981 shares of the stock in a transaction dated Friday, June 9th. The stock was purchased at an average cost of $32.71 per share, for a total transaction of $97,508.51. Following the completion of the acquisition, the insider now owns 5,193 shares of the company’s stock, valued at $169,863.03. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Meghan V. Joyce sold 2,766 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $37.55, for a total value of $103,863.30. Following the completion of the sale, the director now owns 4,224 shares in the company, valued at approximately $158,611.20. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Want More Great Investment Ideas?

A number of analysts have recently issued reports on the stock. BTIG Research dropped their price objective on shares of Guardant Health from $60.00 to $50.00 and set a “buy” rating for the company in a report on Friday, February 24th. Cowen cut their price objective on Guardant Health from $70.00 to $53.00 and set an “outperform” rating for the company in a report on Friday, February 24th. Piper Sandler decreased their price objective on Guardant Health from $35.00 to $30.00 in a report on Monday, May 15th. Credit Suisse Group reduced their price target on shares of Guardant Health from $60.00 to $55.00 in a research report on Wednesday, May 10th. Finally, Citigroup upgraded shares of Guardant Health from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $28.00 to $40.00 in a report on Friday, May 26th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $56.27.

Guardant Health Price Performance

Shares of Guardant Health stock opened at $37.09 on Monday. The business has a 50 day moving average of $27.71 and a 200 day moving average of $29.56. Guardant Health, Inc. has a 52 week low of $20.67 and a 52 week high of $62.75. The company has a market cap of $3.81 billion, a PE ratio of -5.71 and a beta of 0.81. The company has a quick ratio of 5.18, a current ratio of 5.41 and a debt-to-equity ratio of 18.90.

Guardant Health (NASDAQ:GH – Get Rating) last issued its quarterly earnings data on Tuesday, May 9th. The company reported earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.04). Guardant Health had a negative net margin of 137.90% and a negative return on equity of 530.36%. The company had revenue of $128.71 million for the quarter, compared to analysts’ expectations of $117.65 million. As a group, equity research analysts forecast that Guardant Health, Inc. will post -4.71 earnings per share for the current year.

Guardant Health Profile

(Get Rating)

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H.

Further Reading

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Guardant Health and related companies with MarketBeat.com’s FREE daily email newsletter.

Similar Posts